ARO DUX4
Alternative Names: ARO-DUX4Latest Information Update: 11 Sep 2023
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action DUX4L1 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Facioscapulohumeral muscular dystrophy
Most Recent Events
- 04 Sep 2023 Phase-I/II clinical trials in Facioscapulohumeral muscular dystrophy in New Zealand (IV) prior to September 2023 (Arrowhead Pharmaceuticals pipeline, September 2023) (NCT06131983)
- 19 Jul 2023 Arrowhead Pharmaceuticals plans a phase I/IIa trial for Facioscapulohumeral Muscular Dystrophy type 1 in New Zealand
- 17 Jul 2023 Arrowhead Pharmaceuticals files an application for clearance to initiate a phase I/IIa trial to New Zealand Medicines and Medical Devices Safety Authority